Comparison · NCT03036124-be66eb03
Dapa 10 mg vs Placebo: Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Dapa 10 mg vs Placebo: Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure. Trial comparisons, record NCT03036124-be66eb03. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03036124-be66eb03
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.163 | 0.148 | 0.178 | wilson | |
| Risk in group 2 | 0.212 | 0.196 | 0.229 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0491 | -0.0712 | -0.0269 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.768 | 0.681 | 0.866 | log | |
| Odds ratio, group 1 over group 2 | 0.723 | 0.624 | 0.838 | log | |
| Number needed to treat, for one fewer participant with the outcome on Dapa 10 mg than on Placebo | 20.4 | 14 | 37.2 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Dapa 10 mg | Dapagliflozin 10 mg tablets administered orally once daily | 386 | 2,373 | OG000 |
| Group 2 | Placebo | Placebo tablet to match dapagliflozin 10 mg, given once daily per oral use. | 502 | 2,371 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure.
- Description
- Primary efficacy
- Time frame
- Up to 27.8 months.
- Population
Source ClinicalTrials.gov
Trial
- Title
- Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure
- NCT number
- NCT03036124
- Phases
- PHASE3
- Conditions
- Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
- Interventions
- Dapagliflozin, Placebo
- Lead sponsor
- AstraZeneca
- Results first posted
- 2020-09-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03036124?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03036124-be66eb03